Iron overload is the main cause of mortality and morbidity in patients with hereditary hemochromatosis and beta-thalassemia. There is a need for new approaches to prevent and treat these diseases. Intestinal hyperabsorption of iron is a critical mechanism leading to tissue iron overload, and inhibiting intestinal iron absorption presents a potential target. Hypoxia-inducible factors (HIFs) are heterodimeric transcription factors consisting of an alpha-subunit (HIF1-alpha or HIF2-alpha) and beta-subunit (aryl hydrocarbon nuclear translocator (ARNT). Using genetic mouse models and cell lines of HIF signaling, we have shown that intestinal HIF2-alpha is a critical regulator of iron absorption. More recently we demonstrate that HIF2-alpha (but not HIF1-alpha) is the central transcription factor required for regulating intestinal iron absorptive genes and is robustly increased in mouse models of hereditary hemochromatosis and beta-thalassemia. Moreover, intestine-specific HIF-alpha overexpressing mice develop spontaneous iron overload. Based on these observations, we hypothesize that intestinal HIF2-alpha-induced iron absorption is critical in the pathogenesis of iron overload and hematological disorders and presents a novel target for therapy. The long-term objectives of the proposed studies are to elucidate precise mechanisms of how HIF2-alpha regulates intestinal iron absorption as an impetus to the development of therapeutic regimens that can be used to treat hemochromatosis and beta-thalassemia. We will pursue our objectives through four interconnected Specific Aims.
Aim 1 will determine mechanisms by which intestinal HIF2-alpha is activated during iron overload and hematological disorders. This will be examined in intestinal-derived cell lines and Hfe-/-, Hbbth3/+, and Hbbth3/th3 models of hereditary hemochromatosis, beta-thalassemia intermedia, and Cooley's anemia (beta-thalassemia major), respectively.
Aim 2 will assess the molecular mechanisms of iron absorptive gene activation by HIF2-alpha. This will be examined by promoter analysis with a focus on HIF2-alpha iron absorptive target genes.
This Aim will also identify novel target genes of HIF2-alpha using genome-wide promoter binding studies in duodenal tissues from mouse models of hereditary hemochromatosis and beta-thalassemia.
Aims 3 and 4 will determine the requirement for HIF2-alpha in the progression of tissue iron overload in mouse models of hemochromatosis and beta-thalassemia. This will be examined in Hfe-/-, Hbbth3/+, and Hbbth3/th3 mouse models that contain a conditional disruption of HIF2-alpha in the intestine. Successful completion of these studies will increase our understanding of how intestinal iron absorption is regulated, and lays the foundation for pursuing new therapeutic strategies in patients with iron overload and hematological disorders.

Public Health Relevance

Hemochromatosis and beta-thalassemia represent a significant public health problem and new therapies are needed for clinical management of these diseases. Tissue iron overload associated with these diseases present life-threatening complications. The goal of this work is to determine if intestinal HIF2-alpha represents a novel target to restrict iron loading in patients with hemochromatosis and beta-thalassemia.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK095201-04
Application #
8824526
Study Section
Molecular and Cellular Hematology Study Section (MCH)
Program Officer
Roy, Cindy
Project Start
2012-04-01
Project End
2016-07-31
Budget Start
2015-03-01
Budget End
2016-07-31
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Physiology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Razumilava, Nataliya; Gumucio, Deborah L; Samuelson, Linda C et al. (2018) Indian Hedgehog Suppresses Intestinal Inflammation. Cell Mol Gastroenterol Hepatol 5:63-64
Liu, Yan; Jiang, Lin; Sun, Chengxin et al. (2018) Insulin/Snail1 axis ameliorates fatty liver disease by epigenetically suppressing lipogenesis. Nat Commun 9:2751
Kim, D-I; Liao, J; Emont, M P et al. (2018) An OLTAM system for analysis of brown/beige fat thermogenic activity. Int J Obes (Lond) 42:939-945
Sherman, Matthew A; Suresh, Madathilparambil V; Dolgachev, Vladislav A et al. (2018) Molecular Characterization of Hypoxic Alveolar Epithelial Cells After Lung Contusion Indicates an Important Role for HIF-1?. Ann Surg 267:382-391
Triner, Daniel; Xue, Xiang; Schwartz, Andrew J et al. (2017) Epithelial Hypoxia-Inducible Factor 2? Facilitates the Progression of Colon Tumors through Recruiting Neutrophils. Mol Cell Biol 37:
Ji, Tuo; Takabayashi, Hidehiko; Mao, Maria et al. (2017) Regulation and function of bone morphogenetic protein signaling in colonic injury and inflammation. Am J Physiol Gastrointest Liver Physiol 312:G24-G33
Ramakrishnan, Sadeesh K; Shah, Yatrik M (2017) A central role for hypoxia-inducible factor (HIF)-2? in hepatic glucose homeostasis. Nutr Healthy Aging 4:207-216
McEnerney, Laura; Duncan, Kara; Bang, Bo-Ram et al. (2017) Dual modulation of human hepatic zonation via canonical and non-canonical Wnt pathways. Exp Mol Med 49:e413
Xue, Xiang; Bredell, Bryce X; Anderson, Erik R et al. (2017) Quantitative proteomics identifies STEAP4 as a critical regulator of mitochondrial dysfunction linking inflammation and colon cancer. Proc Natl Acad Sci U S A 114:E9608-E9617
Ma, Xiaoya; Zhang, Huabing; Xue, Xiang et al. (2017) Hypoxia-inducible factor 2? (HIF-2?) promotes colon cancer growth by potentiating Yes-associated protein 1 (YAP1) activity. J Biol Chem 292:17046-17056

Showing the most recent 10 out of 37 publications